Literature DB >> 23637192

Foxa1 and foxa2 are required for the maintenance of dopaminergic properties in ventral midbrain neurons at late embryonic stages.

Simon R W Stott1, Emmanouil Metzakopian, Wei Lin, Klaus H Kaestner, Rene Hen, Siew-Lan Ang.   

Abstract

The maintained expression of transcription factors throughout the development of mesodiencephalic dopaminergic (mDA) neurons suggests multiple roles at various stages in development. Two members of the forkhead/winged helix transcription factor family, Foxa1 and Foxa2, have been recently shown to have an important influence in the early development of mDA neurons. Here we present data demonstrating that these genes are also involved in the later maintenance of the mDA system. We conditionally removed both genes in postmitotic mDA neurons using the dopamine transporter-cre mouse. Deletion of both Foxa1 and Foxa2 resulted in a significant reduction in the number of tyrosine hydroxylase (TH)-positive mDA neurons. The decrease was predominantly observed in the substantia nigra region of the mDA system, which led to a loss of TH+ fibers innervating the striatum. Further analysis demonstrated that the reduction in the number of TH+ cells in the mutant mice was not due to apoptosis or cell-fate change. Using reporter mouse lines, we found that the mDA neurons were still present in the ventral midbrain, but that they had lost much of their dopaminergic phenotype. The majority of these neurons remained in the ventral mesencephalon until at least 18 months of age. Chromatin immunoprecipitation suggested that the loss of the mDA phenotype is due to a reduction in the binding of the nuclear orphan receptor, Nurr-1 to the promoter region of TH. These results extend previous findings and demonstrate a later role for Foxa genes in regulating the maintenance of dopaminergic phenotype in mDA neurons.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23637192      PMCID: PMC6618950          DOI: 10.1523/JNEUROSCI.4774-12.2013

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  49 in total

1.  A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth.

Authors:  Qianben Wang; Wei Li; X Shirley Liu; Jason S Carroll; Olli A Jänne; Erika Krasnickas Keeton; Arul M Chinnaiyan; Kenneth J Pienta; Myles Brown
Journal:  Mol Cell       Date:  2007-08-03       Impact factor: 17.970

2.  Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection.

Authors:  Chee Yeun Chung; Hyemyung Seo; Kai Christian Sonntag; Andrew Brooks; Ling Lin; Ole Isacson
Journal:  Hum Mol Genet       Date:  2005-05-11       Impact factor: 6.150

3.  Identification of forkhead transcription factors in cortical and dopaminergic areas of the adult murine brain.

Authors:  Patrick J E C Wijchers; Marco F M Hoekman; J Peter H Burbach; Marten P Smidt
Journal:  Brain Res       Date:  2005-12-27       Impact factor: 3.252

4.  Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1.

Authors:  Jason S Carroll; X Shirley Liu; Alexander S Brodsky; Wei Li; Clifford A Meyer; Anna J Szary; Jerome Eeckhoute; Wenlin Shao; Eli V Hestermann; Timothy R Geistlinger; Edward A Fox; Pamela A Silver; Myles Brown
Journal:  Cell       Date:  2005-07-15       Impact factor: 41.582

5.  Cytoarchitectural distribution of calcium binding proteins in midbrain dopaminergic regions of rats and humans.

Authors:  D A McRitchie; C D Hardman; G M Halliday
Journal:  J Comp Neurol       Date:  1996-01-01       Impact factor: 3.215

6.  Early developmental failure of substantia nigra dopamine neurons in mice lacking the homeodomain gene Pitx3.

Authors:  Marten P Smidt; Simone M Smits; Hans Bouwmeester; Frank P T Hamers; Annemarie J A van der Linden; Anita J C G M Hellemons; Jochen Graw; J Peter H Burbach
Journal:  Development       Date:  2004-03       Impact factor: 6.868

7.  Forebrain and midbrain regions are deleted in Otx2-/- mutants due to a defective anterior neuroectoderm specification during gastrulation.

Authors:  D Acampora; S Mazan; Y Lallemand; V Avantaggiato; M Maury; A Simeone; P Brûlet
Journal:  Development       Date:  1995-10       Impact factor: 6.868

8.  Goosecoid and HNF-3beta genetically interact to regulate neural tube patterning during mouse embryogenesis.

Authors:  S Filosa; J A Rivera-Pérez; A P Gómez; A Gansmuller; H Sasaki; R R Behringer; S L Ang
Journal:  Development       Date:  1997-07       Impact factor: 6.868

9.  Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus.

Authors:  S Srinivas; T Watanabe; C S Lin; C M William; Y Tanabe; T M Jessell; F Costantini
Journal:  BMC Dev Biol       Date:  2001-03-27       Impact factor: 1.978

10.  Foxa1 and Foxa2 regulate multiple phases of midbrain dopaminergic neuron development in a dosage-dependent manner.

Authors:  Anna L M Ferri; Wei Lin; Yannis E Mavromatakis; Julie C Wang; Hiroshi Sasaki; Jeffrey A Whitsett; Siew-Lan Ang
Journal:  Development       Date:  2007-06-27       Impact factor: 6.868

View more
  45 in total

1.  Parkinson-Associated SNCA Enhancer Variants Revealed by Open Chromatin in Mouse Dopamine Neurons.

Authors:  Sarah A McClymont; Paul W Hook; Alexandra I Soto; Xylena Reed; William D Law; Samuel J Kerans; Eric L Waite; Nicole J Briceno; Joey F Thole; Michael G Heckman; Nancy N Diehl; Zbigniew K Wszolek; Cedric D Moore; Heng Zhu; Jennifer A Akiyama; Diane E Dickel; Axel Visel; Len A Pennacchio; Owen A Ross; Michael A Beer; Andrew S McCallion
Journal:  Am J Hum Genet       Date:  2018-11-29       Impact factor: 11.025

2.  Conserved Upstream Regulatory Regions in Mammalian Tyrosine Hydroxylase.

Authors:  Meng Wang; Lilah Fones; John W Cave
Journal:  Mol Neurobiol       Date:  2018-02-05       Impact factor: 5.590

3.  Selection Based on FOXA2 Expression Is Not Sufficient to Enrich for Dopamine Neurons From Human Pluripotent Stem Cells.

Authors:  Julio Cesar Aguila; Alexandra Blak; Joris van Arensbergen; Amaia Sousa; Nerea Vázquez; Ariane Aduriz; Mayela Gayosso; Maria Paz Lopez Mato; Rakel Lopez de Maturana; Eva Hedlund; Kai-Christian Sonntag; Rosario Sanchez-Pernaute
Journal:  Stem Cells Transl Med       Date:  2014-07-14       Impact factor: 6.940

4.  Lysosomes to combat Parkinson's disease.

Authors:  Ole Isacson
Journal:  Nat Neurosci       Date:  2015-06       Impact factor: 24.884

Review 5.  Molecular mechanisms of dopaminergic subset specification: fundamental aspects and clinical perspectives.

Authors:  Jesse V Veenvliet; Marten P Smidt
Journal:  Cell Mol Life Sci       Date:  2014-07-27       Impact factor: 9.261

Review 6.  Maintenance of postmitotic neuronal cell identity.

Authors:  Evan S Deneris; Oliver Hobert
Journal:  Nat Neurosci       Date:  2014-06-15       Impact factor: 24.884

Review 7.  Classification of Midbrain Dopamine Neurons Using Single-Cell Gene Expression Profiling Approaches.

Authors:  Jean-Francois Poulin; Zachary Gaertner; Oscar Andrés Moreno-Ramos; Rajeshwar Awatramani
Journal:  Trends Neurosci       Date:  2020-02-11       Impact factor: 13.837

Review 8.  Complex molecular regulation of tyrosine hydroxylase.

Authors:  Izel Tekin; Robert Roskoski; Nurgul Carkaci-Salli; Kent E Vrana
Journal:  J Neural Transm (Vienna)       Date:  2014-05-28       Impact factor: 3.575

9.  Dopaminergic control of autophagic-lysosomal function implicates Lmx1b in Parkinson's disease.

Authors:  Ariadna Laguna; Nicoletta Schintu; André Nobre; Alexandra Alvarsson; Nikolaos Volakakis; Jesper Kjaer Jacobsen; Marta Gómez-Galán; Elena Sopova; Eliza Joodmardi; Takashi Yoshitake; Qiaolin Deng; Jan Kehr; Johan Ericson; Per Svenningsson; Oleg Shupliakov; Thomas Perlmann
Journal:  Nat Neurosci       Date:  2015-04-27       Impact factor: 24.884

Review 10.  Evaluating cell reprogramming, differentiation and conversion technologies in neuroscience.

Authors:  Jerome Mertens; Maria C Marchetto; Cedric Bardy; Fred H Gage
Journal:  Nat Rev Neurosci       Date:  2016-05-19       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.